[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352653-105":59,"doc-detail-352653-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","vaccinia-related-kinase-2-inhibition-elicits-vulnerability-of-glutathione-metabolism-in-pancreatic-cancer","Vaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer","","Metabolic reprogramming attracts major therapeutic interest, yet identifying tumor subpopulations that respond to metabolism-targeted strategies remains a challenge because metabolic vulnerabilities differ across cancers. Pharmacological experiments show that VRK2-deficient pancreatic cancer cells are highly vulnerable to glutathione (GSH) metabolic pathway inhibition. This vulnerability is driven by reduced basal GSH levels due to impaired plasma membrane expression of SLC7A11. Mechanistically, VRK2 inhibition disrupts ER-to-Golgi trafficking of SLC7A11, lowering GSH biosynthesis and sensitizing cells to ferroptosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/vaccinia-related-kinase-2-inhibition-elicits-vulnerability-of-glutathione-metabolism-in-pancreatic-cancer/352653/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/vaccinia-related-kinase-2-inhibition-elicits-vulnerability-of-glutathione-metabolism-in-pancreatic-cancer/352653.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What vulnerability is induced by VRK2 inhibition in pancreatic cancer cells?","Question",{"text":112,"@type":113},"VRK2-deficient pancreatic cancer cells become highly vulnerable to inhibition of the glutathione (GSH) metabolic pathway, with lower basal GSH levels contributing to this susceptibility.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does VRK2 inhibition affect glutathione synthesis?",{"text":117,"@type":113},"VRK2 inhibition disrupts ER-to-Golgi trafficking of SLC7A11, reducing GSH biosynthesis and sensitizing cells to ferroptosis.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is SLC7A11 central to the mechanism described?",{"text":121,"@type":113},"SLC7A11 controls cystine/glutamate exchange required for cysteine supply, which is a rate-limiting precursor for GSH synthesis; impaired SLC7A11 plasma membrane expression lowers GSH and increases vulnerability.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352653,1790168484,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nVaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer  \nSisi Chen 1,9, Xiaowei Fu 2,9, Tianyue Zhang3, Rui Zhou1, Long Liu4, Liuhai Zeng5, Bin Xu 6 ✉, Hengqing Zhu 7,8 ✉ and Zhiyu Li 7 ✉  \n© The Author(s) 2026  \n\n|  | Metabolic reprogramming has garnered signiﬁcant attention in recent years due to its therapeutic potential in cancer treatment. However, identifying responsive tumor subpopulations remains a major obstacle in developing metabolism-targeted therapies, as metabolic vulnerabilities vary among cancers with different oncogene expression proﬁles. Therefore, elucidating the association between oncogene expression and metabolic characteristics could enable more precise metabolic interventions in clinical settings. Using pharmacological approaches, we demonstrate that VRK2-deﬁcient pancreatic cancer (PC) cells exhibit heightened vulnerability to glutathione (GSH) metabolic pathway inhibition. This susceptibility stems from reduced basal GSH levels caused by impaired plasma membrane expression of SLC7A11 . Mechanistically, we reveal that VRK2 inhibition disrupts endoplasmic reticulum (ER)-to-Golgi trafﬁcking of SLC7A11, consequently diminishing GSH biosynthesis and predisposing PC cells to ferroptosis. Collectively, our ﬁndings establish a novel link between the oncogene VRK2 and GSH synthesis metabolism, providing a molecular |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| basis for developing stratiﬁed metabolic therapies for PC patients. |  |  |\n|  | Cell Death and Disease (2026)17:325; [https://doi.org/10.1038/s41419-026-08573-9](https://doi.org/10.1038/s41419-026-08573-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nPancreatic cancer(PC) is one of the most lethal malignancies with a 5-year survival rate less than 9%[1] . Current epidemiological data rank it as the seventh leading cause of cancer-related mortality worldwide, with projections indicating it may become the second leading cause in the United States by 2030 [2, 3] . Although substantial efforts have been made to improve clinical outcomes, existing therapeutic strategies demonstrate limited efﬁcacy. This therapeutic impasse underscores the urgent need for novel breakthroughs in PC treatment. In recent years, increasing attraction has been paid to metabolic network as for cancer cells have the capability to support survival and growth by adopting extensive metabolic rewiring in response to alterations in internal or external circumstances [4, 5] . Thus, targeting the metabolic reprogramming may provide appealing opportunities to explore novel treatments for PC.  \nOxidative stress caused by high levels of reactive oxygen species(ROS) can lead to cell damage and death. Intracellular ROS levels depend on the balance between ROS generation and clearance, and are also manipulated by antioxidant defense mechanisms [6] . Glutathione (GSH), the most potent endogenous antioxidant identiﬁed to date, safeguards cells by participating in redox reactions that neutralize accumulated ROS [7] . Of note, GSH serves as the terminal product of the GSH synthesis pathway,  \nwhich utilizes cysteine, glutamate, and glycine as primary substrates. This biosynthetic process is mediated by glutamatecysteine ligase (GCL), which includes glutamate-cysteine ligase catalytic subunit(GCLC) and GSH synthetase(GSS) [8] . Cysteine is a rate-limiting precursor substrate for GSH synthesis, and its level is regulated by SLC7A11 encoding the cystine/glutamate transporter XCT, which is primarily responsible for the export of glutamine in exchange for extracellular cystine [9] . Therefore, in order to overcome the survival crisis caused by oxidative stress, cancer cells are likely to exhibit metabolic preferences and undergo metabolic reprogramming, including but not limited to GSH metabolic rewiring.  \nEvidence have shown that the p","cbCaig0a5y5mNo2P","https://ap.wps.com/l/cbCaig0a5y5mNo2P","pdf",6057218,13,"English","# Introduction\n## Pancreatic cancer and unmet therapeutic needs\n## Oxidative stress and the GSH antioxidant system\n## Genetic drivers of metabolic reprogramming\n## VRK kinases and the research rationale","[{\"question\":\"What vulnerability is induced by VRK2 inhibition in pancreatic cancer cells?\",\"answer\":\"VRK2-deficient pancreatic cancer cells become highly vulnerable to inhibition of the glutathione (GSH) metabolic pathway, with lower basal GSH levels contributing to this susceptibility.\"},{\"question\":\"How does VRK2 inhibition affect glutathione synthesis?\",\"answer\":\"VRK2 inhibition disrupts ER-to-Golgi trafficking of SLC7A11, reducing GSH biosynthesis and sensitizing cells to ferroptosis.\"},{\"question\":\"Why is SLC7A11 central to the mechanism described?\",\"answer\":\"SLC7A11 controls cystine/glutamate exchange required for cysteine supply, which is a rate-limiting precursor for GSH synthesis; impaired SLC7A11 plasma membrane expression lowers GSH and increases vulnerability.\"}]","Vaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer | PDF",1790100663,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d3bb537deeed2dacd58278a0b76bb95.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dcdcc223ab5d8e3a9aa336bd84a8df48.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f8122dc2c3028be47b565dfd669ef13.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1061a152b756eda59f9dc345f0568b1b.webp",980,1301]